Preventive Effects of Prasugrel on Cerebrovascular Events Following Percutaneous Coronary Intervention
Stroke · 2025-08 · 56 (8) · 2101-2109
DOI: 10.1161/strokeaha.125.050366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stroke, 2025-08. Verfasst von Hisaki Makimoto und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine (H.M., T. Kabutoya, T. Kohro, Y.O., Y.I., K.K.), Jichi Medical University School of Medic…. Hauptthemen laut MEDLINE: Prasugrel Hydrochloride, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Cerebrovascular Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Dual antiplatelet drug administration is recommended after percutaneous coronary intervention (PCI) stent placement. Although prasugrel, a newer P2Y12 inhibitor, reportedly suppresses cardiovascular events more effectively than the traditional agent clopidogrel, its preventive effects on cerebrovascular disorders remain a topic of ongoing debate. This study aimed to examine the cerebrovascular efficacy and safety of post-PCI prasugrel and clopidogrel using extensive real-world data in Japan. METHODS: Using the CLIDAS (Clinical Deep Data Accumulation System) database, 7412 post-PCI patients who received dual antiplatelet therapy between April 2013 and March 2019 were identified. The primary end point was defined as the incidence of any stroke, while secondary end points included individual ischemic and hemorrhagic cerebrovascular events. The incidence of cerebrovascular events was compared between the prasugrel (2.5–3.75 mg daily; n=2219) and clopidogrel (75 mg daily; n=5193) groups using propensity-score inverse probability of treatment weighting and Fine and Gray models to account for competing risks. RESULTS: Within 1 year after PCI, the prasugrel group had a significantly lower incidence of cerebrovascular events (subdistribution hazard ratio, 0.46 [95% CI, 0.24–0.91]; P =0.027) than the clopidogrel group. The subgroup analyses did not show significant differences in the incidence of ischemic (subdistribution hazard ratio, 0.54 [95% CI, 0.25–1.14]; P =0.11) and hemorrhagic cerebrovascular events (subdistribution hazard ratio, 0.30 [95% CI, 0.084–1.10]; P =0.070) between the use of prasugrel and clopidogrel. One-year health care costs between patients treated with prasugrel and those treated with clopidogrel showed no significant differences. CONCLUSIONS: Our data suggest that post-PCI prasugrel use was associated with lower cerebrovascular events compared with the use of clopidogrel in combination with aspirin. Further research is necessary to substantiate the potential of prasugrel in lowering cerebrovascular risks after post-PCI while upholding a satisfactory safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine (H.M., T. Kabutoya, T. Kohro, Y.O., Y.I., K.K.), Jichi Medical University School of Medicine, Shimotsuke, Japan.
- Data Science Center (H.M., T. Kohro, H. Yamana), Jichi Medical University School of Medicine, Shimotsuke, Japan.
- Institute of Medical Science, The University of Tokyo, Japan (H.M.).
- Department of Real-World Evidence, The University of Tokyo Graduate School of Medicine, Japan (Y.S., H. Yasunaga).
- Division of Clinical Pharmacology, Department of Pharmacology (Y.I.), Jichi Medical University School of Medicine, Shimotsuke, Japan.
- Precision, Inc, Tokyo, Japan (H.S.).
ORCID-Profile: Hisaki Makimoto, Tomoyuki Kabutoya, Takahide Kohro, Yasushi Imai, Kazuomi Kario, Arihiro Kiyosue, Yoshiko Mizuno, Kotaro Nochioka, Masaharu Nakayama, Takamasa Iwai, Yoshihiro Miyamoto, Masanobu Ishii, Taishi Nakamura, Kenichi Tsujita, Naoyuki Akashi, Hideo Fujita, Hideo Yasunaga, Tetsuya Matoba, Ryozo Nagai
Zitieren
APA
Makimoto, H., Sasabuchi, Y., Kabutoya, T., Kohro, T., Yamana, H., Oba, Y., Imai, Y., Kario, K., Sato, H., Kiyosue, A., Mizuno, Y., Nochioka, K., Nakayama, M., Iwai, T., Miyamoto, Y., Ishii, M., Nakamura, T., Tsujita, K., Akashi, N., …, & CLIDAS-PCI Research Group (2025). Preventive Effects of Prasugrel on Cerebrovascular Events Following Percutaneous Coronary Intervention. Stroke, 56(8), 2101-2109. https://doi.org/10.1161/strokeaha.125.050366
Vancouver
Makimoto H, Sasabuchi Y, Kabutoya T, Kohro T, Yamana H, Oba Y, et al. Preventive Effects of Prasugrel on Cerebrovascular Events Following Percutaneous Coronary Intervention. Stroke. 2025;56(8):2101-2109. doi:10.1161/strokeaha.125.050366
BibTeX
@article{Makimoto2025,
author = {Makimoto, Hisaki and Sasabuchi, Yusuke and Kabutoya, Tomoyuki and Kohro, Takahide and Yamana, Hayato and Oba, Yusuke and Imai, Yasushi and Kario, Kazuomi and Sato, Hisahiko and Kiyosue, Arihiro and Mizuno, Yoshiko and Nochioka, Kotaro and Nakayama, Masaharu and Iwai, Takamasa and Miyamoto, Yoshihiro and Ishii, Masanobu and Nakamura, Taishi and Tsujita, Kenichi and Akashi, Naoyuki and Fujita, Hideo and Yasunaga, Hideo and Matoba, Tetsuya and Nagai, Ryozo and CLIDAS-PCI Research Group, CLIDAS-PCI Research Group},
title = {Preventive Effects of Prasugrel on Cerebrovascular Events Following Percutaneous Coronary Intervention},
journal = {Stroke},
year = {2025},
volume = {56},
number = {8},
pages = {2101--2109},
doi = {10.1161/strokeaha.125.050366}
}
EUVIMED